Clinica Baviera (FRA:D9Z) Tariff Resilience Score: 0/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D9Z Clinica Baviera SA FRA:D9Z
100 GF Score
Price €57.20
GF Value €41.46
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Clinica Baviera Tariff Resilience Score?

Clinica Baviera has the Tariff Resilience Score of 0, which implies that the company might have .

Clinica Baviera has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Clinica Baviera might have .

Clinica Baviera  (FRA:D9Z) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Clinica Baviera Tariff Resilience Score Related Terms

FRA:D9Z
100GF Score
Clinica Baviera SA FRA:D9Z
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clinica Baviera (FRA:D9Z) Overvalued in 2026?

Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued. The current stock price of €57.20 is trading 38% above its estimated GF Value™ of €41.46. GuruFocus considers Clinica Baviera to be Significantly Overvalued.

Key valuation signals for FRA:D9Z:

  • Tariff Resilience Score: 0
  • GF Value™: €41.46 vs. price of €57.20 (38% above fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the FRA:D9Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinica Baviera Business Description

Address Paseo de la Castellana 20, Madrid, ESP, 28046
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score

Get the complete analysis for FRA:D9Z

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€57.20
Price
€41.46
GF Value